Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,544 Million (Small Cap)
16.00
NA
2.08%
-0.23
5.70%
1.40
Revenue and Profits:
Net Sales:
180 Million
(Quarterly Results - Jun 2026)
Net Profit:
37 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.0%
0%
25.0%
6 Months
-12.11%
0%
-12.11%
1 Year
-13.26%
0%
-13.26%
2 Years
5.16%
0%
5.16%
3 Years
-21.01%
0%
-21.01%
4 Years
0.19%
0%
0.19%
5 Years
7.29%
0%
7.29%
Shanghai Kaibao Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.64%
EBIT Growth (5y)
23.85%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.34
Tax Ratio
12.57%
Dividend Payout Ratio
48.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.27%
ROE (avg)
6.40%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
0.93
EV to EBIT
13.70
EV to EBITDA
12.32
EV to Capital Employed
0.92
EV to Sales
3.17
PEG Ratio
NA
Dividend Yield
3.11%
ROCE (Latest)
6.68%
ROE (Latest)
5.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
179.70
204.00
-11.91%
Operating Profit (PBDIT) excl Other Income
44.20
40.00
10.50%
Interest
0.00
0.00
Exceptional Items
-2.50
-0.70
-257.14%
Consolidate Net Profit
37.00
37.60
-1.60%
Operating Profit Margin (Excl OI)
194.70%
152.60%
4.21%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -11.91% vs -42.32% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -1.60% vs -29.85% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,140.70
1,455.60
-21.63%
Operating Profit (PBDIT) excl Other Income
301.00
388.70
-22.56%
Interest
0.20
0.10
100.00%
Exceptional Items
-10.70
1.10
-1,072.73%
Consolidate Net Profit
278.00
374.90
-25.85%
Operating Profit Margin (Excl OI)
232.60%
242.10%
-0.95%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -21.63% vs -7.56% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -25.85% vs 14.68% in Dec 2024
About Shanghai Kaibao Pharmaceutical Co., Ltd. 
Shanghai Kaibao Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






